Cumberland Pharmaceuticals begins rolling FDA NDA for Dyscorban in Duchenne muscular dystrophy cardiomyopathy

Cumberland Pharmaceuticals has begun a rolling New Drug Application submission to the FDA for Dyscorban (ifetroban) to treat cardiomyopathy associated with Duchenne muscular dystrophy.

Detected & updated continuously · Source: Nebula